期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肥厚型心肌病患者心源性猝死相关预测指标的临床价值 被引量：7

原文传递
导出
摘要 肥厚型心肌病（HCM）是最常见的心肌病，发病率约1：500，约60％的患者有可询及的家族史，呈常染色体显性遗传。HCM是原发于心肌的遗传性疾病，心室肥厚是其诊断依据，需排除高血压等疾病和运动员心脏肥厚。
作者 李新立
机构地区 南京医科大学第一附属医院心内科
出处 《内科理论与实践》 2012年第5期334-337,共4页 Journal of Internal Medicine Concepts & Practice
关键词 肥厚型心肌病 猝死 危险分层
分类号 R542.2 [医药卫生—心血管疾病]
  • 相关文献

参考文献21

  • 1Nishimura RA, Holmes DR Jr. Clinical practice. Hypertrophic obstructive cardiomyopathy[J]. N Engl J Med,2004, 350(13): 1320-1327.
  • 2Maron B J, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for practice guidelines[J]. J Am Coil Cardiol,2003, 42(9): 1687-1713.
  • 3Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/ American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J]. Circulation, 2006, 114 (10): e385-e484.
  • 4Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population[J]. Circulation, 2000, 102(8): 858-864.
  • 5Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy[J]. Circulation, 2009, 119(13): 1703-1710.
  • 6Isobe N, Toyama T, Taniguchi K, et al. Failure to raise blood pressure during exercise is a poor prognostic sign in patients with hypertrophic non-obstructive cardiomyopathy[J]. Circ J, 2003, 67(3): 191-194.
  • 7Christiaans I, van Engelen K, van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers[J]. Europaee, 2010, 12(3): 313-321.
  • 8Kawasaki T, Azuma A, Asada S, et al. Heart rate turbulence and clinical prognosis in hypertrophic cardiomyopathy and myocardial infarction [J]. Circ J, 2003, 67(7) 601-604.
  • 9Counihan PJ, Fei L, Bashir Y, et al. Assessment of heart rate variability in hypertrophic cardiomyopathy Association with clinical and prognostic features [J]. Circulation, 1993, 88(4 Pt 1): 1682-1690.
  • 10Yanagi S, Yoshinaga M, Horigome H, et al. Heart rate variability and ambulatory blood pressure monitoring in young patients with hypertrophic eardiomyopathy[J]. Circ J, 2004, 68(8): 757-762.

同被引文献57

  • 1SPOHR F, WENZEL V, BOTrIGER BW. Drug treatment and thrombolytics during cardiopulmonary resuscitation [ J ]. Curr Opin Anaesthesiol.2009,19 ( 2 ) : 157 - 165.
  • 2WEINFURT KP, SS, BERGER, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and out- comes[J]. Circulation JT - Circulation,2012,28(9) :69 -74.
  • 3WILLEMS R, SIPIAO KR, HOLEMANS P, et al. Different patterns of angiotenasin and atrial natriuretic peptide secretion in a sheep model[ J]. Cardiovasc Electrophysiol,2009,12(12) :335 - 342.
  • 4CHEN Y J,CHEN YC,TAI CT,et al. Angiotensin Ⅱ and Angio- tensin Ⅱ receptor blocker modulate the arrhythmogenic activity of pulmonaryveins[ J ]. Br J Pharmaeo1,2006,147 ( 1 ) : 12 - 22.
  • 5CHEN YJ,CHEN YG,TAI CT,et at. Angiotensin Ⅱ and Angioten- sin Ⅱ receptor blocker modulate the arrhythmogenic activity of pul- monary veins[ J]. Br J Pharmaco1,2010,147 ( 1 ) : 12 - 22.
  • 6CHEN YJ, CHEN YG, TAI CT, et at. Revertion of atrial fibril- lationwith angiotension - converting enzyme inhibitor sand angio- tensin receptor blocks [J]. Am CollCardiol, 2010, 45:1832 - 1839.
  • 7WACHTELL K, I EHTO M, GERDTS E, et at. Angiotensin Ⅱ receptor blockade reduces new - onset atrial fibrillation and subse- quent stroke compared tatenol the losartan in tervertion for end point reduction in hypertension(LIFE) study [ J ]. Am CollCardiol, 2012,45:720 - 721.
  • 8Masayuki Yamaji,Takayoshi Tsutamoto,Chiho Kawahara,Keizo Nishiyama,Takashi Yamamoto,Masanori Fujii,Minoru Horie.Effect of eplerenone versus spironolactone on cortisol and hemoglobin A 1c levels in patients with chronic heart failure[J].American Heart Journal.2010(5)
  • 9RIKWILLEMS,KARIN R.SIPIDO,PATRICIAHOLEMANS,HUGOECTOR,FRANSWERF,HEINHEIDBüCHEL.Different Patterns of Angiotensin II and Atrial Natriuretic Peptide Secretion in a Sheep Model of Atrial Fibrillation[J].Journal of Cardiovascular Electrophysiology.2003(12)
  • 10Saif S. Rathore,Alan K. Berger,Kevin P. Weinfurt,Kevin A. Schulman,William J. Oetgen,Bernard J. Gersh,Allen J. Solomon.Acute Myocardial Infarction Complicated by Atrial Fibrillation in the Elderly: Prevalence and Outcomes[J].Circulation: Journal of the American Heart Association.2000(9)

引证文献7

二级引证文献62

内科理论与实践
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部